| Title: |
Post-vaccination SARS-CoV-2 infections and antibody responses after BNT162b2 in patients with severe obesity: a retrospective cohort study |
| Authors: |
Kara, Zehra; Ak, Tumay; Demir, Ahmet Numan; Akçin, Rüveyda; Dinç, Harika Öykü; Taşkın, Halit Eren; Gareayaghi, Nesrin; Kocazeybek, Bekir; Yumuk, Volkan Demirhan |
| Source: |
Frontiers in Endocrinology ; volume 17 ; ISSN 1664-2392 |
| Publisher Information: |
Frontiers Media SA |
| Publication Year: |
2026 |
| Collection: |
Frontiers (Publisher - via CrossRef) |
| Description: |
Aim The aim of this study was to describe the frequency of post-vaccination SARS-CoV-2 infection and to compare SARS-CoV-2 IgG antibody levels between patients with severe obesity and individuals without obesity after two doses of the BNT162b2 vaccine. Methods One hundred two consecutive patients with severe obesity seen in the obesity outpatient clinic and 54 individuals without obesity who visited a vaccination outpatient clinic were included in the study. Inactivated Severe Adult Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG levels of these two groups were measured four weeks after administration of two doses of BNT162b2 vaccine. SARS-CoV-2 infection was defined as a PCR-confirmed infection documented in hospital records during the 12-month follow-up after completion of two-dose BNT162b2 vaccination. PCR testing was performed only when participants presented to the hospital with clinical suspicion of COVID-19 and was not conducted as routine screening. Clinical characteristics, protective measures and contact history were also queried. Results There was a statistically significant difference in SARS-CoV-2 infection rates after vaccination between the patients with severe obesity (n=28, 27%) and individuals without obesity (n=3, 5%) (p=0.001). In patients with severe obesity, SARS-CoV-2 IgG levels after BNT162b2 vaccination were lower in the group with SARS-CoV-2 infection than in the group without SARS-CoV-2 infection [2697 (1096-8955); 8103 (2208-26903) AUml, respectively] (p=0.008). The antibody levels of those with severe fatigue were lower than those without these complaints [2440 (365-4447); 8955 (2440-16317) AUml, respectively] (p=0.03). A loss of taste or smell was observed in 75% of patients with severe obesity but was not observed in individuals without obesity (p=0.03). In patients with severe obesity, those with taste/smell loss had statistically significantly lower SARS-CoV-2 IgG titres than those without severe obesity [2568 (400-4830); 9526 (2611-16810) AUml, p: 0.02]. Multiple logistic ... |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| DOI: |
10.3389/fendo.2026.1759985 |
| DOI: |
10.3389/fendo.2026.1759985/full |
| Availability: |
https://doi.org/10.3389/fendo.2026.1759985; https://www.frontiersin.org/articles/10.3389/fendo.2026.1759985/full |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.18A014BA |
| Database: |
BASE |